HC Wainwright Issues Pessimistic Outlook for MOLN Earnings

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) – Research analysts at HC Wainwright lowered their Q2 2026 EPS estimates for Molecular Partners in a report released on Monday, July 6th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.45) per share for the quarter, down from their previous estimate of ($0.44). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Molecular Partners’ Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.81) EPS, Q1 2027 earnings at ($0.47) EPS, Q2 2027 earnings at ($0.42) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.38) EPS and FY2027 earnings at ($1.65) EPS.

Other analysts have also issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research report on Friday, April 10th. TD Cowen reaffirmed a “buy” rating on shares of Molecular Partners in a report on Monday, March 16th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Molecular Partners has a consensus rating of “Hold” and an average price target of $8.38.

Molecular Partners Stock Up 2.2%

NASDAQ MOLN opened at $4.09 on Wednesday. The company has a market cap of $165.15 million, a PE ratio of -2.11 and a beta of 1.08. Molecular Partners has a 52 week low of $3.41 and a 52 week high of $5.36. The firm’s 50-day simple moving average is $3.99 and its two-hundred day simple moving average is $4.27.

Molecular Partners (NASDAQ:MOLN) last released its earnings results on Monday, May 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02).

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Molecular Partners stock. SmartHarvest Portfolios LLC boosted its holdings in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) by 26.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,543 shares of the company’s stock after buying an additional 3,232 shares during the period. SmartHarvest Portfolios LLC’s holdings in Molecular Partners were worth $62,000 as of its most recent SEC filing. Institutional investors and hedge funds own 26.55% of the company’s stock.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.